newsfilter
← Latest News
PR Newswire·

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BIOA
  • BioArctic AB's partner Eisai presented real-world LEADER study results at the Alzheimer's Association International Conference® (AAIC®) 2026 in London on July 14, 2026.
  • Nearly 83% of 427 patients with early Alzheimer's disease remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months.
  • Treatment persistence was high, with nearly 87% of patients choosing to remain on Leqembi therapy.
  • Findings were consistent across sex, race, ethnicity, APOE genotype, and baseline disease stages (MCI or mild AD dementia).
  • The LEADER study was a three-year, multicenter, retrospective real-world analysis integrating data from 13 US sites, including 432 patients who received at least seven infusions.
  • In the maintenance dosing population, 81% of 155 patients transitioning to every-four-weeks intravenous treatment remained stable or improved, while 85.7% of 14 patients on weekly subcutaneous treatment maintained their disease stage.
  • Overall safety was consistent with the US FDA-approved label, with amyloid-related imaging abnormalities (ARIA) observed in 12.3% of patients.
  • ARIA-E occurred in 6.3% of patients, ARIA-H in 7.9%, and isolated ARIA-H in 6.0%, with most cases being asymptomatic or mild.
  • No new ARIA-E events, macrohemorrhages, or intracerebral hemorrhages greater than 1cm were reported during every-four-weeks intravenous maintenance therapy.
  • Safety observations for ARIA were consistent across APOE ε4 carrier statuses, with no severe ARIA reported in APOE ε4 homozygotes.
  • Antithrombotic therapy usage did not meaningfully alter the incidence of ARIA compared to patients not receiving such medications.
  • Leqembi is approved in 53 countries, with subcutaneous formulations under regulatory review or approved in regions including the US, UK, China, and Japan.
  • BioArctic holds commercialization rights for the Nordic region under its long-term collaboration with Eisai.